Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases - Trial NCT02755428
Access comprehensive clinical trial information for NCT02755428 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Chinese Academy of Sciences and is currently status unknown. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
retinal pigment epithelium transplantation
Interventional
biological
Sponsor & Location
Chinese Academy of Sciences
Timeline & Enrollment
Early Phase 1
Jan 01, 2018
Dec 01, 2020
Primary Outcome
safety and tolerance of transplantation
Summary
This project intends to transplant human embryonic stem cells derived retinal pigment
 epitheliums into subretinal space of patients to treat dry age-related macular
 degeneration(dry-AMD).And we will assess the safety and efficacy of RPE transplants to treat
 dry AMD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02755428
Non-Device Trial